

## Literaturverzeichnis Mesotherapie

1. Venkataram Mysore **Mesotherapy in Management of Hairloss - Is it of Any Use?** PMID: 21188025 PMCID: PMC3002412 DOI: [10.4103/0974-7753.66914](https://doi.org/10.4103/0974-7753.66914)
2. „**Mesotherapie ist ganz klar im Kommen**“ Gespräch mit Dr. Michael Weidmann, Vorsitzender des Präsidiums des Netzwerk-Globalhealth, zur zweiten statistischen Erhebung, dem Meso Report des Netzwerk-ÄsthetikMeso. KosMed 1.2017, 50-52
3. Hana Duchková, Marta Hašková **Female androgenetic alopecia, a survey of causes and therapeutic options** Cas Lek Cesk 2015;154(2):90-4 PMID: 25994911
4. Michael Weidmann, Martin Torzicky, Gisela Funke und Dirk Eichelberg **Alternative Methoden zur Behandlung von diffusem Effluvium und Alopecia Areata: Mesotherapie und Platelet Rich Plasma Therapie** KosMed 5.15, 192-194
5. Mohamed El-Komy<sup>1</sup>, Akmal Hassan<sup>1</sup>, Amira Tawdy<sup>1</sup>, Mohamed Solimon<sup>2</sup>, Mohamed Abdel Hady<sup>1</sup> **Hair loss at injection sites of mesotherapy for alopecia** PMID: 28160387 DOI: [10.1111/jocd.12320](https://doi.org/10.1111/jocd.12320)
6. Stephanie Alexandra Ihrsky **Mesotherapy in trichology** Cas Lek Cesk Summer 2017;156(3):145-146. PMID: 28722459
7. Michael Weidmann **Verbesserung des Hautstatus und Behandlung von Haarausfall weiblicher Patienten: Die Bedeutung der Mesotherapie für ästhetische Indikationen.** ästhetische dermatologie & kosmetologie 03 · 2018
8. American Society for Dermatologic Surgery (January 2006) Technology report: mesotherapy. Available at <http://www.asds.net/TechnologyReportMesotherapy.aspx>. Accessed 15 February 2008
9. American Society of Plastic Surgeons (2005) Policy statement: mesotherapy. Available at [www.plasticsurgery.org/medical\\_professionals/Policy\\_Statements/loader.cfm?url=/commonspot/security/getfile.cfm&PageID=16075](http://www.plasticsurgery.org/medical_professionals/Policy_Statements/loader.cfm?url=/commonspot/security/getfile.cfm&PageID=16075). Accessed 11 February 2008
10. Amin S, Phelps R, Goldberg D (2006) Mesotherapy for facial skin rejuvenation: a clinical, histologic, and electron microscopic evaluation. Dermatol Surg 32(12):1467-1472
11. Amin SP, Phelps RG, Goldberg DJ. Mesotherapy for facial skin rejuvenation: A clinical, histologic, and electron microscopic evaluation. Dermatol Surg 32: 1467, 2006.
12. Andre P. Hyaluronic acid and its use as a "rejuvenation" agent in cosmetic dermatology. Simin Cutan Med Surg 2004; **23**: 218-222.
13. ASPS/PSEF (2007) Non-invasive fat-melting procedures - hype or reality? Emerging trends discussed at American Society of Plastic Surgeons Annual Meeting, October 27, 2007. Available at [www.plasticsurgery.org/media/press\\_releases/Non-Invasive-Fat-Melting-Procedures-Hype-or-Reality.cfm](http://www.plasticsurgery.org/media/press_releases/Non-Invasive-Fat-Melting-Procedures-Hype-or-Reality.cfm). Accessed 15 February 2008
14. Bernlohr DA, Jenkins AE, Bennaars AA. Adipose tissue and lipid metabolism. In G. Bernardi, D. E. Vance, and J. E. Vance (Eds.), Biochemistry of Lipids, Lipoproteins and Membranes, 4th Ed. Amsterdam: Elsevier, 2002. P. 275.
15. Bessis D, Guilhou JJ, Guillot B. Localized urticaria pigmentosa triggered by mesotherapy. Dermatology 2004;209:343-4.
16. Borkan GA, Gerzof SG, Robbins AH, et al. Assessment of abdominal fat content by computed tomography. Am J Clin Nutr 36: 172, 1982.
17. Branda C, Fernandes N, Mesquita N, et al. Abdominal haematoma: A mesotherapy complication. Acta Derm Venerol 85: 446, 2005.
18. Brown S (2006) The science of mesotherapy: chemical anarchy. Aesthetic Surg J 26:95-98
19. Bryant R (2004) Controversial mesotherapy: could it be the next Botox? Dermatol Times 25:1
20. Calikoglu E, Sorg O, Tran C, et al. UVA and UVB decrease the expression of CD44 and hyaluronate in mouse epidermis, which is counteracted by topical retinoids. Photochem Photobiol 2006; **82**: 1342-1347.

21. Caruso MK, Roberts AT, Bissoon L, Self KS, Guillot TS, Greenway FL (2007) An evaluation of mesotherapy solutions for inducing lipolysis an treating cellulite. *J Plast Reconstr Aesthet Surg* October 20. doi:10.1016/j.bjps.2007.03.039. (Epub ahead of print)
22. Centers for Disease Control and Prevention. Outbreak of mesotherapy-associated skin reactions: District of Columbia area, January–February 2005. *MMWR Morb Mortal Wkly Rep* 54: 1127, 2005.
23. Clissold SP, Lynch S, Sorkin EM. Buflofomedil: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peripheral and cerebral vascular disease. *Drugs* 33: 430, 1987
24. de Rigal J, Escoffier C, Querleux B, et al. Assessment of aging of the human skin by in vivo ultrasonic imaging. *J Invest Dermatol* 1989; **93**: 621-624
25. Donofrio LM (2007) Mesotherapy. *Cosmet Dermatol* 20:97-98
26. Furlong W, Cunanan BA, Weymouth LA, Pearson JI, Sockwell DC, Jenkins SR, Marr J, Tipple M, Shah DD, Blythe D, Lum GR, Glymph AC, Davies-Cole JO, Srinivasam A, Meites E, Snenshine RH (2005) Outbreak of mesotherapy-associated skin reactions - District of Columbia area, January–February 2005. *MMWR Morb Mortal Wkly Rep* 54:1127-1130
27. Gniadecka M, Jemec GBE. Quantitative evaluation of chronological ageing and photoageing in vivo: studies on skin echogenicity and thickness. *Br J Dermatol* 1998; **139**: 815-821.
28. Gniadecka M. Effects of ageing on dermal echogenicity. *Skin Res Tech* 2001; **7**: 204-207.
29. Greenway FL, Bray GA, Heber D. Topical fat reduction. *Obes Res* 3: 561S, 1995.
30. Gryskiewicz JM, Adams WP Jr (2006) Plastic surgeons rate the "hot topics". *Aesthetic Surg J* 26:479-484
31. Hughes TA, Stentz F, Gettys T, Smith SR. Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjects. *Metabolism* 55: 26, 2006.
32. Iorizzo M, De Padova MP, Tosti A. Biorejuvenation : theory and practice. *Clin Dermatol* 2008; **26**: 177-181.
33. Jemec GBE, Gniadecka M, Ulrich J. Ultrasound in dermatology. *Eur J Dermatol* 2000; **10**: 492-497.
34. Kalil A (2006) Aesthetic mesotherapy: the US approach and contribution. *Cosmet Dermatol* 19:753-758
35. Kaya G, Saurat JH. Dermatoporosis: a chronic cutaneous insufficiency/fragility syndrome. Clinicopathological features, mechanisms, prevention and potential treatments. *Dermatology* 2007; **215**: 284-294.
36. Kaya G, Tran C, Sorg O, et al. Hyaluronate fragments reverse skin atrophy by a CD44-dependent mechanism. *PLoS Med* 2006; **3**: e493.
37. Kerscher M, Bayrhammer J, Reuther T. Rejuvenating influence of a stabilized hyaluronic acid-based gel of nonanimal origin on facial skin aging. *Dermatol Surg* 2008; **34**: 720-726.
38. Kim HK, Kim YW, Kim HJ. The evaluation of the effect of aminophylline injection to subcutaneous fat reduction (in Korean). *Korean Soc Aesthetic Plast Surg* 9: 17, 2003.
39. Koda M, Senda M, Kamba M, Kimura K, Murawaki Y. Sonographic subcutaneous and visceral fat indices represent the distribution of body fat volume. *Abdom Imaging* 32: 387, 2006.
40. Lacarrubba F, Nardone B, Tedeschi A, Nordstrom R, Micali G. Ultrasound evaluation of mesotherapy for skin rejuvenation. In: Tosti A, De Padova MP, eds. *Atlas of mesotherapy in skin rejuvenation*. London, UK: Informa Healthcare Ltd, 2007.
41. Lawrence N (2003) Commentary: no smoking gun: findings from a national survey of office-based cosmetic surgery adverse event reporting. *Dermatol Surg* 29:1099
42. Lee DP, Chang SE. Subcutaneous nodules showing fat necrosis owing to mesotherapy. *Dermatol Surg* 2005;31:250-1.
43. Lübeck RP, Berneburg M, Trelles M, et al. How best to halt and/or revert UV-induced skin ageing: strategies, facts and fiction. *Exp Dermatol* 2008; **17**: 228-240.
44. Matarasso A, Pfeifer TM. Mesotherapy for body contouring. *Plast Reconstr Surg* 115: 1420, 2005.

45. Mesotherapy and Estetik. Available at <http://www.mesotherapy.com/faq/>. Accessed 11 February 2008
46. Micali G, Lacarrubba F, Tedeschi A, Nodstrom R (2008) Mesotherapy for rejuvenation of photoaged skin: Ultrasound evaluation. *J Am Acad Dermatol* 58:AB23
47. Monticone M, Barbarino A, Testi C, et al. Symptomatic efficacy of stabilizing treatment versus laser therapy for sub-acute low back pain with positive tests for sacroiliac dysfunction: A randomized clinical controlled trial with 1 year follow-up. *Eura Medicophys* 40: 263: 2004
48. Nagore E, Ramos P, Botella-Estrada R, et al. Cutaneous infection with *Mycobacterium fortuitum* after localized microinjections (mesotherapy) treated successfully with a triple drug regimen. *Acta Derm Venereol* 2001;81:291-3.
49. Park YY, Cellulite an Aesthetic Mesotherapy. Seoul: Hanmi Medical Publishing, 2004. P. 134.
50. Pistor M. [What is mesotherapy?]. *Chir Dent Fr* 1976;46:59-60.
51. Rallan D, Harland CC. Ultrasound in dermatology - basic principles and applications. *Clin Exp Dermatol* 2003; **28**: 632-638.
52. Ramos-e, -Silva M, da Silva Carneiro SC. Elderly skin and its rejuvenation. Products an procedures for the aging skin. *J Cosmet Dermatol* 2007; **6**:40-50.
53. Rivera-Olivero IA, Guevara A, Escalona A, et al. Softtissue infections due to non-tuberculous mycobacteria following mesotherapy: What is the price of beauty. *Eferm Infect Microbiol Clin* 24: 302, 2006.
54. Rohrich RJ (2005) Mesotherapy: what ist it? does it work? *Plast Reconstr Surg* 115:1425
55. Rohrich RJ. Mesotherapy: What ist it? Does it work? *Plast Reconstr Surg* 115: 1425, 2005.
56. Rose PT, Morgan M. Histological changes associated with mesotherapy for fat dissolution. *J Cosmet Laser Ther* 2005;7:17-9.
57. Rose PT, Morgan M. Histological changes associated with mesotherapy for fat dissolution. *J Cosmet Laser Ther* 7: 17, 2005.
58. Rosina P, Chieregato C, Miccolis D, et al. Psoriasis and side-effects of mesotherapy. *Int J Dermatol* 40: 581, 2001.
59. Rotunda A, Kolodney MS (2006) Mesotherapy an phosphatidylcholine injektions: historical clarification and review. *Dermatol Surg* 32:465-480
60. Rotunda AM, Kolodney MS. Mesotherapy an phosphatidylcholine injection: Historical clarification and review. *Dermatol Surg* 32: 465, 2006.
61. Rotunda AM, Suzuki H, Moy RL, Kolodney MS. Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for lokalized fat dissolution. *Dermatol Surg* 2004;30:1001-8.
62. Salas AP, Asaadi M. Aesthetic application of mesotherapy: A preliminary report (Abstract). Presented at the Annual Meeting of the American Society for Aesthetic Plastic Surgery, Vancouver, British Columbia, Canada, April 17, 2004.
63. Sandby-Moller J, Wulf HC. Ultrasonographic subepidermal low-echogenic band, dependence of age an body site. *Skin Res Tech* 2004; **10**: 57-63.
64. Schmults CD, Phelps R, Goldberg DJ. Nonablative facial remodeling erythema reduction and histologic evidence of new collagen formation using a 300 micosecond 1064-nm Nd: YAG laser. *Arch Dermatol* 2004;140:1373-6.
65. Seidell JC, Bakker CJ, van der Kooy K. Imaging techniques for measuring adipose-Tissue distribution: A comparison between computed tomography an 1.5-T magnetic resonance. *Am J Clin Nutr* 51: 953, 1990.
66. Singh K (2006) Nonsurgical facial rejuvenation. *J Int Med Sci Acad* 19:158-164
67. Soncini G, Costantino C. The treatment of pathologic calcification of shoulder tendons with E.D.T.A. bisodium salt by mesotherapy. *Acta Biomed Ateneo Parmense* 69: 133, 1998.
68. Stachowski J, Botts K, Rine L, Kato D, Pollock J (2006) Mesotherapy: cosmetic applications. *Int J Pharmaceut Compound* 10:331-334
69. Tennstedt D, Lachapelle JM. Cutaneous adverse effects of mesotherapy. *Ann Dermatol Venerol* 124: 192, 1997.

70. Tokunaga K, Matsuzawa Y, Ishikawa K, et al. A novel technique for the determination of body fat by computed tomography. *Int J Obes* 7: 437, 1983.
71. Tonkovic-Capin M, Riddle CC, Schweiger ES, Aires DJ, Manson SH, Tonkovic-Capin V (2007) Brief discussion: medicolegal aspects of consent and checklists for common cosmetic procedures. *Comet Dermatol* 20(5):291-294
72. Verdier-Sévrain S, Bonté F, Gilchrest B. Biology of estrogens in skin: implications for skin aging. *Exp Dermatol* 2006; **15**: 83-94.
73. Verpaele A, Strand A. Restylane SubQ, a non-animal stabilizes hyaluronic acid gel for soft tissue augmentation of the mid- and lower face. *Aesthet Surg J* 2006; **26**: 510-517.
74. Waller JM, Maibach HI. Age and skin structure and function, a quantitative approach (I): blood flow, thickness, and ultrasound echogenicity. *Skin Res Tech* 2005; **11**: 221-235.
75. Weits T, van der Beek EJ, Wedel M, et al. Computed tomography measurement of abdominal fat deposition in relation to anthropometry. *Int J Obes* 12: 217, 1988.
76. Wies L, Kerscher M. Native hyaluronic acid in dermatology - results of an expert meeting. *J Dtsch Dermatol Ges* 2008; **6**: 176-180.
77. Yaar M, Gilchrest BA. Photoageing: mechanism, prevention and therapy. *Br J Dermatol* 2007; **15**: 874-877.
78. Zanaboni L, Bonfiglioli D, Sommariva D, D'Adda D, Fasoli A. Increase in lipolysis and decrease in plasma-heparin lipoprotein lipase activity and alpha 1 lipoprotein level after aminophylline in man. *Eur J Clin Pharmacol* 19: 349, 1981.